Xbrane Biopharma AB (publ) (STO:XBRANE)
Sweden · Delayed Price · Currency is SEK 10.25
+0.10 (0.99%)
Jul 24, 2026, 5:08 PM CET
Xbrane Biopharma AB Market Cap
Xbrane Biopharma AB has a market cap or net worth of 209.14 million as of July 24, 2026. Its market cap has decreased by -52.31% in one year.
Market Cap
209.14M
Enterprise Value
223.36M
Revenue
83.30M
Ranking
n/a
PE Ratio
n/a
Stock Price
10.25
ChartMarket Cap Chart
Since February 3, 2016, Xbrane Biopharma AB's market cap has increased from 131.05M to 209.14M, an increase of 59.59%. That is a compound annual growth rate of 4.56%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 24, 2026 | 209.14M | -0.49% |
| Dec 30, 2025 | 210.17M | -14.54% |
| Dec 30, 2024 | 245.94M | -17.28% |
| Dec 29, 2023 | 297.31M | -86.83% |
| Dec 30, 2022 | 2.26B | -13.94% |
| Dec 30, 2021 | 2.62B | 58.03% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Isofol Medical AB | 236.84M |
| IRLAB Therapeutics AB | 197.79M |
| Simris Group AB (PUBL) | 182.22M |
| Elicera Therapeutics AB | 175.52M |
| Xintela AB | 162.78M |
| Diamyd Medical AB | 162.42M |
| Initiator Pharma | 159.50M |
| Nanologica AB | 144.00M |